Skip to main content
OpenTrials
Completed

NCT Number: NCT04859868

Non-pharmaceutical Motion Sickness Mitigation

The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

21 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be able to consent to participate themselves.
  • Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ.
  • No racial ethnic groups will be excluded.
  • Must be fluent speakers of English.

Exclusion criteria

  • History of vestibular disease, migraine, or significant balance disorder.
  • Traumatic brain injury.
  • Recent middle ear infection or recent motion sickness (within 72 hours).
  • History of severe motion sensitivity.
  • Women who are pregnant.

Treatment and study plan

Galvanic Vestibular Stimulation

Device

Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.

Primary outcomes

  1. Motion Perception

    Time frame: During the rotation of the chair, approximately 1 hr

    Motion Perception verbal report using a visual analog scale (1-100) will be recorded during the rotation of the chair (1=feeling no motion perception; 100=feeling the maximum motion perception)

Secondary outcomes

  1. Motion Sickness Questionnaire

    Time frame: During the rotation of the chair, approximately 1 hr

    subjective experiences of motion sickness in a scale of 0-10 (0=not at all; 10=most severe)

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 26, 2021
Registry last updated
Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.